Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Apogee Therapeutics, Inc. - Common Stock
(NQ:
APGE
)
86.05
-2.24 (-2.54%)
Streaming Delayed Price
Updated: 12:25 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apogee Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
July 06, 2025
Webcast to be held Monday, July 7th at 8:00 a.m. ET
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
May 29, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Why Is Apogee Therapeutics Stock Trading Higher On Monday?
↗
May 12, 2025
Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing.
Via
Benzinga
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
May 12, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
May 12, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
May 01, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
March 20, 2025
Via
Benzinga
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
↗
March 03, 2025
Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
Via
Benzinga
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
March 03, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
March 03, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
February 28, 2025
Webcast to be held Monday, March 3rd at 8:30 a.m. ET
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate in Upcoming March Investor Conferences
February 25, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
↗
February 12, 2025
Via
Benzinga
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
February 03, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
January 29, 2025
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
December 10, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
December 02, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces Agenda for Virtual R&D Day
November 29, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
↗
November 25, 2024
Via
Benzinga
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
November 18, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
November 12, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
November 04, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases
October 24, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
October 16, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
September 12, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
September 09, 2024
From
Apogee Therapeutics
Via
GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
August 19, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024
↗
August 12, 2024
APGE stock results show that Apogee Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
August 12, 2024
From
Apogee Therapeutics, LLC
Via
GlobeNewswire
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
July 18, 2024
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
